Drug Safety

, Volume 28, Issue 2, pp 137–152 | Cite as

The Safety of Newer Antidepressants in Pregnancy and Breastfeeding

Review Article

Abstract

The pregnancy and postpartum periods are considered to be relatively high risk times for depressive episodes in women, particularly for those with pre-existing psychiatric illnesses. Therefore, it may be necessary to start or continue the pharmacological treatment of depression during these two timeframes. Hence, the aim of this review is to examine the effects on the fetus and infant of exposure, through the placenta and maternal milk, to the following drugs: fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram, mirtazapine, venlafaxine, reboxetine and bupropion.

The teratogenic risks, perinatal toxicity and effects on the neurobehavioural development of newborns associated with exposure through the placenta or maternal milk to these medications need to be carefully assessed before starting psychopharmacological treatment in pregnant or lactating women. In spite of the limitations of some of the studies reviewed, the older selective serotonin-reuptake inhibitors (SSRIs) [as we await further data regarding escitalopram] and venlafaxine seem to be devoid of teratogenic risks. By contrast, the data concerning possible consequences related to exposure to SSRIs via the placenta and breastmilk on neonatal adaptation and long-term neurocognitive infant’s development are still controversial. Nevertheless, a number of reports have shown that an association between placental exposure to SSRIs and adverse but self-limiting effects on neonatal adaptation may exist. In addition, the information on both teratogenic and functional teratogenic risks associated with exposure to bupropion, mirtazapine and reboxetine is incomplete or absent; at present, these compounds should not be used as first-line agents in the pharmacological treatment of depression in pregnancy and breastfeeding.

Untreated depression is not without its own risks since mothers affected by depression have a negative impact on the emotional development of their children and major depression, especially when complicated by a delusional component, may lead to the mother attempting suicide and infanticide. Consequently, clinicians need to help mothers weigh the risks of prenatal exposure to drugs for their babies against the potential risks of untreated depression and abrupt discontinuation of pharmacological treatment. Given these situations, we suggest that choosing to administer psychopharmacological treatment in pregnant or breastfeeding women with depression will result primarily from a careful evaluation of their psychopathological condition; currently, the degree of severity of maternal disease appears to represent the most relevant parameter to take this clinical decision.

Supplementary material

40264_2012_28020137_MOESM1_ESM.pdf (76 kb)
Supplementary material, approximately 78 KB.

References

  1. 1.
    Sundstrom IM, Bixo M, Bjorn I, et al. Prevalence of psychiatric disorders in gynaecologic outpatients. Am J Obstet Gynecol 2001; 184(2): 8–13PubMedCrossRefGoogle Scholar
  2. 2.
    Bixo M, Sundstrom-Poromaa I, Bjorn I, et al. Patients with psychiatric disorders in gynaecologic practice. Am J Obstet Gynecol 2001; 185(2): 396–402PubMedCrossRefGoogle Scholar
  3. 3.
    Andersson L, Sundstrom-Poromaa I, Bixo M, et al. Point prevalence of psychiatric disorders during the second trimester of pregnancy: a population-based study. Am J Obstet Gynecol 2003; 189(1): 148–54PubMedCrossRefGoogle Scholar
  4. 4.
    Halbreich U. Prevalence of mood symptoms and depression during pregnancy: implications for clinical practice and research. CNS Spectr 2004; 9(3): 177–84PubMedGoogle Scholar
  5. 5.
    Glotlib I, Whiffen V, Mount J, et al. Prevalence rates and demographic characteristic in pregnancy and postpartum. J Consult Clin Psychol 1989; 57: 269–74CrossRefGoogle Scholar
  6. 6.
    Newport DJ, Hostetter A, Arnold A, et al. The treatment of postpartum depression: minimizing infant exposure. J Clin Psychiatry 2002; 63Suppl. 7: 31–44PubMedGoogle Scholar
  7. 7.
    Gold LH. Postpartum disorders in primary care: diagnosis and treatment. Prim Care 2002 Mar; 29(1): 27–41PubMedCrossRefGoogle Scholar
  8. 8.
    Weimberg MK, Tronick EL. Maternal depression and infant maladjustment: a failure of mutual regulation. In: Nospitz JD, editor. Handbook of child and adolescent psychiatry. New York: John Wiley & Sons, 1997: 122–27Google Scholar
  9. 9.
    Weimberg MK, Tronick EL. The impact of maternal psychiatric illness on infant development. J Clin Psychiatry 1998; 59Suppl. 2: 53–61Google Scholar
  10. 10.
    Kornstein SG. The evaluation and management of depression in women across the life span. J Clin Psychiatry 2001; 62Suppl. 24: 11–7PubMedGoogle Scholar
  11. 11.
    Brown CS. Depression and anxiety disorders. Obstet Gynecol Clin North Am 2001; 28(2): 241–68PubMedCrossRefGoogle Scholar
  12. 12.
    Elia J, Katz IR, Simpson GM. Teratogenicity of psychotherapeutic medications. Psychopharmacol Bull 1987; 23: 531–86PubMedGoogle Scholar
  13. 13.
    Elia J, Simpson GM. Antidepressant medications during pregnancy and lactation: fetal teratogenic and toxic effects. In: Amsterdam JD, editor. Pharmacotherapy of depression: application for the outpatient practitioner. New York: Marcel Dekker, 1990: 337–79Google Scholar
  14. 14.
    Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996; 335(14): 1010–5PubMedCrossRefGoogle Scholar
  15. 15.
    Addis A, Koren G. Safety of fluoxetine during the first trimester of pregnancy. Psychol Med 2000; 30(1): 89–94PubMedCrossRefGoogle Scholar
  16. 16.
    Pastusak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993; 269(17): 2246–8CrossRefGoogle Scholar
  17. 17.
    Cohen LS, Heller VL, Bailey JW, et al. Birth outcomes following prenatal exposure to fluoxetine. Biol Psychiatry 2000; 48(10): 996–1000PubMedCrossRefGoogle Scholar
  18. 18.
    Goldstein DJ, Corbin LA, Sundell KL. Effects of first-trimester fluoxetine exposure on the newborn. Obstet Gynecol 1997; 89: 713–8PubMedCrossRefGoogle Scholar
  19. 19.
    Diav-Citrin O, Shechtman S, Weinbaum D, et al. Pregnancy outcome after gestational exposure to paroxetine: a prospective controlled study cohort [abstract]. Teratology 2002; 65(6): 298Google Scholar
  20. 20.
    Sinclair J, Birtwistle J, Baldwin D. The Tolerability of Venlafaxine. Rev Comptemp Pharmacother 1998; 9: 333–44Google Scholar
  21. 21.
    Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors. JAMA 1998; 279: 609–10PubMedCrossRefGoogle Scholar
  22. 22.
    McElhatton PR, Garbis HM, Elefant E, et al. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants: a collaborative study of the European Network of Teratology Information Services (ENTIS). Reprod Toxicol 1996; 10(4): 285–94PubMedCrossRefGoogle Scholar
  23. 23.
    Chambers CD, Dick LM, Felix RJ, et al. Pregnancy outcomes in women who use sertraline [abstract]. Teratology 1999; 59(6): 376Google Scholar
  24. 24.
    Ericson A, Kallen B, Wilholm BE. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999; 55(7): 503–8PubMedCrossRefGoogle Scholar
  25. 25.
    Einarson A, Selby P, Koren G. Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counselling. J Psychiatry Neurosci 2001; 26(1): 44–8PubMedGoogle Scholar
  26. 26.
    Vedernikov Y, Bolanos S, Bytautiene E, et al. Effects of fluoxetine on contractile activity of pregnant rat uterine rings. Am J Obstet Gynecol 2000; 182(2): 296–9PubMedCrossRefGoogle Scholar
  27. 27.
    Wisner KL, Gelemberg AJ, Leonard H, et al. Pharmacologic treatment of depression during pregnancy. JAMA 1999; 282(13): 1264–9PubMedCrossRefGoogle Scholar
  28. 28.
    Chambers CD, Anderson PO, Thomas RG, et al. Weight gain in infants breastfed by mothers who take fluoxetine. Pediatrics 1999; 104(5): 1098–102CrossRefGoogle Scholar
  29. 29.
    Campino GA. Cardiac arrhythmia in a newborn associated with fluoxetine use during pregnancy [letter]. Ann Pharmacother 2002; 36(3): 533–4CrossRefGoogle Scholar
  30. 30.
    McAnally LE, Threlked KR, Dreyling CA. Case report of a syncopal episode associated with fluoxetine. Ann Pharmacother 1992; 26: 1090–1PubMedGoogle Scholar
  31. 31.
    Gram LF. Fluoxetine. N Eng J Med 1994; 331: 1354–60CrossRefGoogle Scholar
  32. 32.
    Spencer MJ. Fluoxetine hydrochloride (Prozac) toxicity in a neonate. Pediatrics 1993; 92: 721–2PubMedGoogle Scholar
  33. 33.
    Nordeng H, Lindemann R, Perminov KV, et al. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr 2001; 90(3): 288–91PubMedCrossRefGoogle Scholar
  34. 34.
    Oberlander TF, Misri S, Fitzgerald CE, et al. Is polypharmacy associated with transient neonatal symptoms following prenatal psychotropic medication exposure? [abstract]. Pediatr Res 2003; 53(4 Pt 2): 426AGoogle Scholar
  35. 35.
    Pitfield SF, Oberlander TF, Fitzgerald CE, et al. Prolonged prenatal psychotropic medication exposure reduces T-helper (CD4+) cells in neonates at birth [abstract]. Pediatr Res 2000; 47(4 Pt 2): 76AGoogle Scholar
  36. 36.
    Oberlander TF, Grunau RE, Fitzgerald CE, et al. Prenatal psychotropic medication exposure alters acute neonatal pain response. Pediatr Res 2002; 51: 443–53PubMedCrossRefGoogle Scholar
  37. 37.
    Rampono J, Proud S, Hackett LP, et al. A pilot study of newer antidepressant concentration in cord and maternal serum and possible effects in the neonate. Int J Neuropsychopharmacol, 2004; 7(3): 329–4PubMedCrossRefGoogle Scholar
  38. 38.
    Suri R, Altshuler L, Hendrick V, et al. The impact of depression and fluoxetine treatment on obstetrical outcome. Arch Women Ment Health, 2004; 7(3): 193–200CrossRefGoogle Scholar
  39. 39.
    Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997; 336: 258–62PubMedCrossRefGoogle Scholar
  40. 40.
    Nulman I, Rovet J, Stewart DE, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002; 159(11): 1889–95PubMedCrossRefGoogle Scholar
  41. 41.
    Heikkinen T, Ekblad U, Palo P, et al. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther 2003; 73(4): 330–7PubMedCrossRefGoogle Scholar
  42. 42.
    Taddio A, Ito S, Koren G. Excretion of fluoxetine and its metabolite in human breast milk. Pediatr Res 1994; 35(1A): 443–5Google Scholar
  43. 43.
    Kristensen JH, Ilett KF, Hackett LP, et al. Distribution and excretion of fluoxetine and norfluoxetine in human milk. Clin Pharmacol 1999; 48(4): 521–7Google Scholar
  44. 44.
    Taddio A, Ito S, Koren G. Excretion of fluoxetine and its metabolite, norfluoxetine, in human breast milk. J Clin Pharmacol 1996; 36(1): 42–7PubMedGoogle Scholar
  45. 45.
    Yoshida K, Smith B, Craggs M, et al. Fluoxetine in breast-milk and developmental outcome of breast-fed infants. Br J Psychiatry 1997; 172: 175–9CrossRefGoogle Scholar
  46. 46.
    Birnbaum CS, Cohen LS, Bailey JW, et al. Serum concentrations of antidepressants and benzodiazepines in nursing infants: a case series. Pediatrics 1999; 104(1): e11PubMedCrossRefGoogle Scholar
  47. 47.
    Hendrick V, Stowe ZN, Altshuler LL, et al. Fluoxetine and norfluoxetine concentrations in nursing infants and breast milk. Biol Psychiatry 2001; 50(10): 775–82PubMedCrossRefGoogle Scholar
  48. 48.
    Lester BM, Cucca J, Andreozzi L, et al. Possible association between fluoxetine hydrochloride and colic in an infant. J Am Acad Child Adolesc Psychiatry 1993; 32(6): 1253–5PubMedCrossRefGoogle Scholar
  49. 49.
    Hale TW, Shurm S, Grossberg M. Fluoxetine toxicity in a breastfed infant. Clin Pediatr 2001; 40: 681–4CrossRefGoogle Scholar
  50. 50.
    Chambers CD, Anderson PO, Thomas RG, et al. Weight gain in infants breastfed by mothers who take fluoxetine. Pediatrics 1999; 104(5): e61PubMedCrossRefGoogle Scholar
  51. 51.
    Berle JO, Steen VM, Aamo TO, et al. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome P450 genotypes. J Clin Psychiatry, 2004; 65(9): 1228–34PubMedCrossRefGoogle Scholar
  52. 52.
    Kristensen JH, Hackett LP, Kohan R, et al. The amount of fluvoxamine in milk is unlikely to be a cause of adverse effects in breastfed infants. J Hum Lact 2002; 18(2): 139–43PubMedCrossRefGoogle Scholar
  53. 53.
    Wright S, Dawling S, Ashford JJ. Excretion of fluvoxamine in breast milk [letter]. Br J Psychiatry 1991; 31: 209Google Scholar
  54. 54.
    Yoshida K, Smith B, Craggs M, et al. Fluvoxamine in breast milk and infant development. Br J Clin Pharmacol 1997; 44: 210–1PubMedGoogle Scholar
  55. 55.
    Hendrick V, Fukuchi A, Altshuler L, et al. Use of sertraline, paroxetine and fluvoxamine by nursing women. Br J Psychiatry 2001; 179: 163–6PubMedCrossRefGoogle Scholar
  56. 56.
    Misri S, Kim J, Riggs KW, et al. Paroxetine levels in postpartum depressed women, breast milk and infant serum. J Clin Psychiatry 2000; 61(11): 828–32PubMedCrossRefGoogle Scholar
  57. 57.
    Begg EJ, Duffull SB, Saunders DA, et al. Paroxetine in human milk. Br J Clin Pharmacol 1999; 48(2): 142–7PubMedCrossRefGoogle Scholar
  58. 58.
    Ohman R, Hagg S, Carleborg L, et al. Excretion of paroxetine into breast milk. J Clin Psychiatry 1999; 60(8): 519–23PubMedCrossRefGoogle Scholar
  59. 59.
    Santos RP, Pergolizzi JJ. Transient neonatal jitteriness due to maternal use of sertraline (Zoloft®). J Perinatol 2004; 24(6): 392–4PubMedCrossRefGoogle Scholar
  60. 60.
    Dodd S, Stocki A, Buist A, et al. Sertraline in paired blood plasma and breast-milk samples from nursing mothers. Hum Psychopharmacol 2000; 15(4): 261–4CrossRefGoogle Scholar
  61. 61.
    Mammen PK, Perel JM, Rudolph G, et al. Sertraline and norsertraline levels in three breastfed infants. J Clin Psychiatry 1997; 58(3): 100–3PubMedCrossRefGoogle Scholar
  62. 62.
    Stowe ZN, Hostetter AL, Owens MJ, et al. The pharmacokinetics of sertraline excretion into human breast milk: determinants of infant serum concentrations. J Clin Psychiatry 2003; 64(1): 73–80PubMedCrossRefGoogle Scholar
  63. 63.
    Kristensen JH, Ilett KF, Dusci LJ, et al. Distribution and excretion of sertraline and N-desmethylsertraline in human milk. Br J Clin Pharmacol 1998; 45(5): 453–7PubMedCrossRefGoogle Scholar
  64. 64.
    Wisner KL, Perel JM, Blumer J. Serum sertraline and Ndesmethylsertraline levels in breast-feeding mother-infant pairs. Am J Psychiatry 1998; 155(5): 690–2PubMedGoogle Scholar
  65. 65.
    Zeskind PS, Stephens LE. Association of maternal-SSRI use during pregnancy and disrupted neonatal sleep organization [abstract]. Pediatr Res 2003; 53(4 Pt 2): 71AGoogle Scholar
  66. 66.
    Rampono J, Kristensen JH, Hackett LP, et al. Citalopram and demethylcitalopram in human milk; distribution, excretion and effects in breast fed infants. Br J Clin Pharmacol 2000; 50(3): 263–8PubMedCrossRefGoogle Scholar
  67. 67.
    Spigset O, Carieborg L, Ohman R, et al. Excretion of citalopram in breast milk. Br J Clin Pharmacol 1997; 44(3): 295–8PubMedCrossRefGoogle Scholar
  68. 68.
    Piontek CM, Wisner KL, Perel JM, et al. Serum fluvoxamine levels in breastfed infants. J Clin Psychiatry 2001; 62(2): 111–3PubMedCrossRefGoogle Scholar
  69. 69.
    Unfred CL, Chambers CD, Felix R, Kao K, Dick L, Alvarado S, et al. Birth outcomes among pregnant women taking paroxetine (Paxil®: update presented at the Organization of Teratology Service, 14th Annual Conference; 2001 Jun, Teratology, 63(6)Google Scholar
  70. 70.
    Costei AM, Kozer E, Ho T, et al. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002; 156(11): 1129–32PubMedCrossRefGoogle Scholar
  71. 71.
    Gerola O, Fiocchi S, Rondini G. Antidepressant therapy in pregnancy: a review from the literature and report of a suspected paroxetine withdrawal syndrome in a newborn. Riv Ital Pediatr 1999; 25(1): 216–8Google Scholar
  72. 72.
    Morag I, Batash D, Keidar R, et al. Paroxetine use throughout pregnancy: does it pose any risk to the neonate? J Toxicol Clin Toxicol 2004; 42(1): 97–100PubMedCrossRefGoogle Scholar
  73. 73.
    Salvia-Roiges MD, Garcia L, Gonce-Mellegren A, et al. Neonatal convulsions and subarachnoid hemorrhage after in utero exposure to paroxetine. Rev Neurol 2003; 36(8): 724–6PubMedGoogle Scholar
  74. 74.
    Laine K, Kytola J, Bertilsson L. Severe adverse effects in a newborn with two defective CYP2D6 alleles after exposure to paroxetine during late pregnancy. Ther Drug Monit, 2004; 26(6): 685–7PubMedCrossRefGoogle Scholar
  75. 75.
    Morison SJ, Grunau RE, Oberlander TF, et al. Infant social behavior and development in the first year of life following prolonged prenatal psychotropic medication exposure. Pediatr Res 2001; 49(4 Pt 2): 28AGoogle Scholar
  76. 76.
    Stowe ZN, Cohen LS, Hostetter A, et al. Paroxetine in human breast milk and nursing infants. Am J Psychiatry 2000; 175(2): 185–9CrossRefGoogle Scholar
  77. 77.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington (DC): American Psychiatric Press, 1994Google Scholar
  78. 78.
    Merlob P, Stahl B, Sulkes J. Paroxetine during breast-feeding: infant weight gain and maternal adherence to counsel. Eur J Pediatr, 2004; 163(3): 135–9PubMedCrossRefGoogle Scholar
  79. 79.
    Hendrick V, Smith LM, Suri R, et al. Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol 2003; 188(3): 812–5PubMedCrossRefGoogle Scholar
  80. 80.
    Altshuler LL, Burt VK, McMullen M, et al. Breastfeeding and sertraline: a 24-hour analysis. J Clin Psychiatry 1995; 56(6): 243–5PubMedGoogle Scholar
  81. 81.
    Stowe ZN, Owens MJ, Landry JC, et al. Sertraline and desmethilsertraline in human breast milk and nursing infants. Am J Psychiatry 1997; 154(9): 1255–60PubMedGoogle Scholar
  82. 82.
    Epperson R, Czarkowski KA, Ward-O Brien D, et al. Maternal sertraline treatment and serotonin transport in breast-feeding mother-infant pairs. Am J Psychiatry 2001; 158(10): 1631–7PubMedCrossRefGoogle Scholar
  83. 83.
    Laine K, Heikkinen T, Ekblad U, et al. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotoninergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 2003; 60(7): 720–6PubMedCrossRefGoogle Scholar
  84. 84.
    Heikkinen T, Ekblad U, Kero P, et al. Citalopram in pregnancy and lactation. Clin Pharmacol Ther 2002; 72(2): 184–91PubMedCrossRefGoogle Scholar
  85. 85.
    Jensen PN, Olesen OV, Bertelsen A, et al. Citalopram and desmethylcitalopram concentrations in breast milk and in serum of mother and infant. Ther Drug Monit 1997; 19(2): 236–9PubMedCrossRefGoogle Scholar
  86. 86.
    Lee A, Woo J, Ito S. Frequency of infant adverse events that are associated with citalopram use during breast-feeding. Am J Obstet Gynecol 2004; 190(1): 218–21PubMedCrossRefGoogle Scholar
  87. 87.
    Shmidt K, Olesen OV, Jensen PN. Citalopram and breastfeeding: serum concentration and side effects in the infant. Biol Psychiatry 2000; 47(2): 164–5CrossRefGoogle Scholar
  88. 88.
    Escitalopram: Drugdex Drug Evaluations. Original publication: 12/2001; most recent revision: 03/2003: 1-27Google Scholar
  89. 89.
    Simhandl C, Zhoglami A, Pinder R. Pregnancy during use of mirtazapine. 11th European Congress of Psychoneuropharmacology; 1998; Paris, France. Abstract P.1.038Google Scholar
  90. 90.
    Kesim M, Yaris F, Kadioglu M, et al. Mirtazapine use in two pregnant women: is it safe? [letter]. Teratology 2002; 66: 204PubMedCrossRefGoogle Scholar
  91. 91.
    Montgomery SA. Safety of mirtazapine: a review. Int Clin Psychopharmacol 1995; 10Suppl. 4: 37–45PubMedCrossRefGoogle Scholar
  92. 92.
    Montgomery SA, Reimitz PE, Zivkov M. Mirtazapine versus amitriptyline in the long-term of depression: a double-blind, placebo-controlled study. Int Clin Psychopharmacol 1998; 13(2): 63–73PubMedCrossRefGoogle Scholar
  93. 93.
    Guelfi JD, Annsseau M, Timmermann L, et al. Mirtazapine versus venlafaxine in hospitalised severely depressed patients with melancholic features. J Clin Psychopharmacol 2001; 21(4): 425–31PubMedCrossRefGoogle Scholar
  94. 94.
    Saks BR. Treatment of depression, anxiety, and hyperemesis gravidarum in the pregnant patient. A report of 7 cases.Arch Women Mental Health 2001; 3(4): 165–70CrossRefGoogle Scholar
  95. 95.
    Rodhe A, Dembinski J, Dorn C. Mirtazapine (Remergil) for treatment resistant hyperemesis gravidarum: rescue of a twin pregnancy. Arch Gynecol Obstet 2003; 268(3): 219–21CrossRefGoogle Scholar
  96. 96.
    Rodhe A, Almut D, Cristoph D. Intravenous mirtazapine for treatment resistant hyperemesis gravidarum. Poster presented at 2nd World Congress of Mental Health, Washington D.C., 2004 Mar 17-20; p 075Google Scholar
  97. 97.
    Yaris F, Kadioglu M, Kesim M, et al. Newer antidepressants in pregnancy: a prospective outcome of a case series. Reprod Toxicol, 2004; 19(2): 235–8PubMedCrossRefGoogle Scholar
  98. 98.
    Yaris F, Yaris E, Kadiouglu M, et al. Use of polypharmacotherapy in pregnancy: a prospective outcome in a case. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28(3): 603–5PubMedCrossRefGoogle Scholar
  99. 99.
    Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 5th ed. Baltimore: Williams & Wilkins, 1998Google Scholar
  100. 100.
    Aichhorn W, Whitworth AB, Weiss U, et al. Mirtazapine and breast-feeding letter. Am J Psychiatry, 2004; 161(12): 2325PubMedCrossRefGoogle Scholar
  101. 101.
    Einarson A, Fatoye B, Sarkar M, et al. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry 2001; 158: 1728–30PubMedCrossRefGoogle Scholar
  102. 102.
    de Moor RA, Mourad L, ter Haar J, et al. Withdrawal symptoms in a neonate following exposure to venlafaxine during pregnancy. Ned Tijdschr Geneesked 2003; 147(28): 1370–2Google Scholar
  103. 103.
    Ilett KF, Kristensen JH, Hackett LP, Paech M, Kohan R, Rampono J. Distribution of venlafaxine and its O-desmethyl metabolite in human milk and their effects in breastfed infants; Br J Clin Pharmacol 2002; 53: 17–22PubMedCrossRefGoogle Scholar
  104. 104.
    Ilett KF, Hackett LP, Dusci LJ, et al. Distribution and excretion of venlafaxine and O-desmethylvenlafaxine in human milk. Br J Clin Pharmacol 1998; 45(5): 459–62PubMedCrossRefGoogle Scholar
  105. 105.
    Hendrick V, Altshuler L, Wertheimer A, et al. Venlafaxine and breast-feeding [letter]. Am J Psychiatry 2001; 158: 12CrossRefGoogle Scholar
  106. 106.
    Data on file 1. Investigator’s brochure. Bracco SpA, 2000Google Scholar
  107. 107.
    Gentile S, de Bartolomeis A, Muscettola G. Farmaci psicotropi di II generazione: possibilità e limiti di utilizzo in gravidanza ed allattamento. Giorn Ital Psicopat 2000; 6(1): 62–78Google Scholar
  108. 108.
    Einarson A, Koren G. New antidepressants in pregnancy. Can Fam Physician 2004; 50(2): 227–9PubMedGoogle Scholar
  109. 109.
    Boshier A, Wilton LV, Shakir SA. Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000. Eur J Clin Pharmacol 2003; 59(10): 767–73PubMedCrossRefGoogle Scholar
  110. 110.
    Briggs GG, Samson JH, Ambrose PJ, et al. Excretion of bupropion in breast milk. Ann Pharmacother 1993; 27(4): 431–3PubMedGoogle Scholar
  111. 111.
    Baab SW, Peindl KS, Piontek CM, et al. Serum bupropion levels in two breastfeeding mother-infant pairs. J Clin Psychiatry 2002; 63(10): 910–1PubMedCrossRefGoogle Scholar
  112. 112.
    Haas JS, Kaplan CP, Barenboim D, et al. Bupropion in breast milk: an exposure assessment for potential treatment to prevent post-partum tobacco use. Tob Control 2004; 13(1): 52–6PubMedCrossRefGoogle Scholar
  113. 113.
    Chaudron LH, Schoenecker CJ. Bupropion and breastfeeding: a case of possible infant seizure [letter]. J Clin Psychiatry, 2004; 65(6): 881–2PubMedCrossRefGoogle Scholar
  114. 114.
    Cohen L, Heller V, Rosembaum J. Treatment guidelines for psychotropic drug use in pregnancy. Psychosomatics 1989; 30: 25–33PubMedCrossRefGoogle Scholar
  115. 115.
    Wrate RM, Rooney AC, Thomas PF, et al. Postnatal depression and child development. Br J Psychiatry 1985; 146: 622–7PubMedCrossRefGoogle Scholar
  116. 116.
    Whiffen VE, Gotlib IH. Infants of postpartum depressed mothers: temperament and cognitive status. J Abnorm Psychol 1989; 98: 274–9PubMedCrossRefGoogle Scholar
  117. 117.
    Wen W, Walker M. The use of selective serotonin reuptake inhibitors in pregnancy. Obstet Gynaecol Can 2004; 26(9): 819–22Google Scholar
  118. 118.
    Appleby L, Warner R, Whitton A, et al. A controlled study of fluoxetine and cognitive-behavioural counselling in the treatment of postnatal depression. BMJ 1997 Mar 29; 314(7085): 932–6PubMedCrossRefGoogle Scholar
  119. 119.
    Segre LS, Stuart S, O’Hara MW. Interpersonal psychotherapy for antenatal and postpartum depression. Primary Psychiatry 2004; (3): 52–6Google Scholar
  120. 120.
    Misri S, Reebye P, Corral M, et al. The use of paroxetine and cognitive-behavioral therapy in postpartum depression and anxiety: a randomized controlled trial. J Clin Psychiatry, 2004; 65(9): 1236–41PubMedCrossRefGoogle Scholar
  121. 121.
    Miller LJ. Use of electroconvulsive therapy during pregnancy. Hosp Community Psychiatry 1994; 45: 440–50Google Scholar
  122. 122.
    Rossi A, Barraco A, Donda P. Fluoxetine: a review on evidence based medicine. Ann Gen Hosp Psychiatry, 2004; 3(1): 2PubMedCrossRefGoogle Scholar
  123. 123.
    Gupta S, Masand PS, Rangwani S. Selective reuptake inhibitors in pregnancy and lactation. Obstet Gynecol Surv, 1998; 53(12): 733–6PubMedCrossRefGoogle Scholar
  124. 124.
    Casper RC, Fleisher BE, Lee-Ancajas JC, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 2003; 142(4): 402–8PubMedCrossRefGoogle Scholar
  125. 125.
    Zeskind PS, Stephen LE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Obstet Gynaecol Surv 2004; 59(8): 564–6CrossRefGoogle Scholar
  126. 126.
    Morrison JL, Riggs KW, Chien C, et al. Chronic maternal fluoxetine infusion in pregnant sheep: effects on the maternal and fetal hypothalamic-pituitary-adrenal axes. Pediatr Res 2004; 56(1): 40–6PubMedCrossRefGoogle Scholar
  127. 127.
    Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004; 158(4): 312–6PubMedCrossRefGoogle Scholar
  128. 128.
    Oberlander TF, Misri S, Colleen E, et al. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry 2004; 65(2): 230–7PubMedCrossRefGoogle Scholar
  129. 129.
    Gentile S. SSRIs in pregnancy and lactation with emphasis on neurodevelopmental outcome. CNS Drugs. In pressGoogle Scholar
  130. 130.
    Weissman AM, Lewy BT, Hartz AJ, et al. Pooled analysis of antidepressant levels in lactating women, breast milk, and nursing infants. Am J Psychiatry 2004; 161(6): 1066–78PubMedCrossRefGoogle Scholar
  131. 131.
    Nurnberg HG. Breast feeding and psychotropic agents. Am J Psychiatry, 1981; 138: 120–1PubMedGoogle Scholar
  132. 132.
    de Vries TW, de Jong-van de Berg LTW, Hadders-Algra M. Paroxetine during lactation: is it really safe for the infant? [letter]. Acta Paediatr, 2004; 93: 1406–7PubMedCrossRefGoogle Scholar
  133. 133.
    Misri S, Sivertz K. Tricyclic drugs in pregnancy and lactation: a preliminary report. Int J Psychiatry Med 1991; 21: 157–71PubMedCrossRefGoogle Scholar
  134. 134.
    Ward RK, Zamorski MA. Benefits and risks of psychiatric medications during pregnancy. Am Fam Physician 2002; 66(4): 629–36PubMedGoogle Scholar
  135. 135.
    Nonacs R, Cohen LS. Assessment and treatment of depression during pregnancy: an update. Psychiatr Clin North Am 2003; 26(3): 547–62PubMedCrossRefGoogle Scholar
  136. 136.
    Baum LA, Misri S. Selective serotonin reuptake inhibitors in pregnancy and lactation. Harv Rev Psychiatry 1996; 4(3): 117–25PubMedCrossRefGoogle Scholar
  137. 137.
    Falterman LG, Richardson DJ. Small left colon syndrome associated with maternal ingestion of psychotropic drugs. J Pediatr 1980; 97: 300–10Google Scholar
  138. 138.
    Shearer WT, Schreiner RL, Marschall RE. Urinary retention in a neonate secondary to maternal ingestion of nortriptyline. J Pediatr 1972; 81: 221–4Google Scholar
  139. 139.
    Cohen LS, Altshuler LL, Stowe ZN, et al. Reintroduction of antidepressant therapy across pregnancy in women who previously discontinued treatment: a preliminary retrospective study. Psychother Psychosom, 2004; 73(4): 255–8PubMedCrossRefGoogle Scholar
  140. 140.
    Hosletter A, Stowe ZN, Strader Jr JR, et al. Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications. Depress Anxiety 2000; 11(2): 51–7CrossRefGoogle Scholar
  141. 141.
    Nulman I, Gargaun S, Koren G. Suboptimal pharmacotherapy for depression in pregnancy [abstract]. Clin Pharmacol Ther 2003; 73(2): 28CrossRefGoogle Scholar
  142. 142.
    Marcus SM, Flynn HA, Blow FC, et al. Depressive symptoms among pregnant women screened in obstetrics settings. J Women’s Health (Larchmt) 2003; 12(4): 373–80CrossRefGoogle Scholar
  143. 143.
    Koren G. Discontinuation syndrome following late pregnancy exposure to antidepressants. Arch Pediatr Adolesc Med 2004; 158(4): 307–8PubMedCrossRefGoogle Scholar
  144. 144.
    Cohen LS, Nonacs R, Viguera AC, et al. Diagnosis and treatment of depression during pregnancy. CNS Spectr 2004; 9(3): 209–16PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.Department of Mental HealthASL Salerno 1, Operative Unit District n. 4Cava de’ Tirreni (Salerno)Italy

Personalised recommendations